Table 1.
Baseline characteristics at study entry in all participants, low- and high-risk groups
| All participants | Low-risk group NT-proBNP < 125 ng/L (n = 2549) | High-risk group NT-proBNP ≥ 125 ng/L (n = 3766) | P-value low risk vs. high risk | |
|---|---|---|---|---|
| Congestive heart failure, n (%) | 168 (2.4) | 9 (0.4) | 69 (1.8) | <0.001 |
| Hypertension, n (%) | 3548 (51.7) | 1251 (49.1) | 1975 (52.4) | 0.009 |
| Diabetes mellitus, n (%) | 785 (11.4) | 280 (11.0) | 412 (10.9) | |
| Prior stroke/TIA, n (%) | 556 (8.1) | 180 (7.1) | 278 (7.4) | |
| Vascular disease, n (%) | 474 (6.9) | 95 (3.7) | 297 (7.9) | <0.001 |
| Female gender, n (%) | 3708 (54.0) | 1260 (49.4) | 2247 (59.7) | <0.001 |
| CHA2DS2-VASc | ||||
| Mean ± SD | 3.4 ± 1.0 | 3.3 ± 1.0 | 3.5 ± 1.0 | <0.001 |
| Median (IQR) | 3 (1) | 3 (1) | 3 (1) | |
| OAC treatment, n (%) | 602 (8.8) | 27 (1.1) | 76 (2.0) | 0.003 |
| Systolic BP, mean ± SD | 138 ± 17.2 | 140 ± 19.1 | <0.001 | |
| Diastolic BP, mean ± SD | 82 ± 9.6 | 81 ± 10.7 | <0.001 | |
| Height (cm), mean ± SD | ||||
| All | 170 ± 9.0 | 170 ± 9.1 | ||
| Women | 164 ± 6.1 | 164 ± 6.1 | ||
| Men | 177 ± 6.4 | 178 ± 6.6 | <0.001 | |
| Weight (kg), mean ± SD | ||||
| All | 76 ± 13.1 | 73 ± 13.7 | <0.001 | |
| Women | 70 ± 12.0 | 68 ± 12.2 | <0.001 | |
| Men | 81 ± 11.5 | 81 ± 12.0 | ||
| BMI (kg/m2), mean ± SD | ||||
| All | 26 ± 3.8 | 25 ± 4.0 | <0.001 | |
| Women | 26 ± 4.2 | 25 ± 4.4 | <0.001 | |
| Men | 26 ± 3.3 | 26 ± 3.4 | ||
BMI, body mass index; BP, blood pressure; IQR, interquartile range; NT-proBNP, N-terminal B-type natriuretic peptide; OAC, oral anticoagulation; SD, standard deviation; TIA, transient ischaemic attack.